DE602007012458D1 - Verfahren zur behandlung von entzündungserkrankungen - Google Patents

Verfahren zur behandlung von entzündungserkrankungen

Info

Publication number
DE602007012458D1
DE602007012458D1 DE602007012458T DE602007012458T DE602007012458D1 DE 602007012458 D1 DE602007012458 D1 DE 602007012458D1 DE 602007012458 T DE602007012458 T DE 602007012458T DE 602007012458 T DE602007012458 T DE 602007012458T DE 602007012458 D1 DE602007012458 D1 DE 602007012458D1
Authority
DE
Germany
Prior art keywords
pharmaceutically acceptable
acceptable salts
treatment
inflammatory diseases
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007012458T
Other languages
English (en)
Inventor
Andrew Reaume
Heather Hain
Michael Saporito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MELIOR DISCOVERY Inc
Original Assignee
MELIOR DISCOVERY Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MELIOR DISCOVERY Inc filed Critical MELIOR DISCOVERY Inc
Publication of DE602007012458D1 publication Critical patent/DE602007012458D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Surgical Instruments (AREA)
DE602007012458T 2006-11-10 2007-11-09 Verfahren zur behandlung von entzündungserkrankungen Active DE602007012458D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86531506P 2006-11-10 2006-11-10
PCT/US2007/084214 WO2008060982A1 (en) 2006-11-10 2007-11-09 Methods for treating inflammatory conditions

Publications (1)

Publication Number Publication Date
DE602007012458D1 true DE602007012458D1 (de) 2011-03-24

Family

ID=39401998

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007012458T Active DE602007012458D1 (de) 2006-11-10 2007-11-09 Verfahren zur behandlung von entzündungserkrankungen

Country Status (5)

Country Link
US (3) US8716294B2 (de)
EP (1) EP2083824B1 (de)
AT (1) ATE497767T1 (de)
DE (1) DE602007012458D1 (de)
WO (1) WO2008060982A1 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608094B2 (en) 1999-10-06 2003-08-19 Torrent Pharmaceuticals Ltd. Compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
US20060286046A1 (en) * 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
WO2008101693A2 (en) 2007-02-22 2008-08-28 Beiersdorf Ag Cosmetic and pharmaceutical applications of n-acylated amino acids and structurally related compounds

Also Published As

Publication number Publication date
US9408844B2 (en) 2016-08-09
US20140227209A1 (en) 2014-08-14
ATE497767T1 (de) 2011-02-15
US8716294B2 (en) 2014-05-06
EP2083824B1 (de) 2011-02-09
EP2083824A1 (de) 2009-08-05
WO2008060982A1 (en) 2008-05-22
EP2083824A4 (de) 2009-11-25
US20170173004A1 (en) 2017-06-22
US20080161319A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
ATE495743T1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EA201001865A1 (ru) Противовоспалительные агенты
DE602007006010D1 (de) Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
WO2008089307A3 (en) Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
MX2008012479A (es) Tratamiento de enfermedades neurodegenerativas.
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
EA201790653A1 (ru) Способ лечения болезни альцгеймера и других расстройств
EA201100609A1 (ru) Способы лечения воспаления
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA200971053A1 (ru) Способы лечения кожных язв
EA200970483A1 (ru) Применение пролекарств габапентина и прегабалина для лечения шума в ушах
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
ATE511835T1 (de) Biophosphonate zur behandlung von endometriose
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
ATE533488T1 (de) Verfahren und formulierungen zur modulierung von lyn-kinaseaktivität und behandlung assoziierter erkrankungen